151 related articles for article (PubMed ID: 17718719)
1. Mu-opioid receptor ligands lack receptor subtype selectivity in the aequorin luminescence-based calcium assay.
Fichna J; Staniszewska R; Poels J; Vanden Broeck J; Janecka A
Chem Biol Drug Des; 2007 Sep; 70(3):247-53. PubMed ID: 17718719
[TBL] [Abstract][Full Text] [Related]
2. [D-1-Nal4]endomorphin-2 is a potent micro-opioid receptor antagonist in the aequorin luminescence-based calcium assay.
Fichna J; Piestrzeniewicz M; Gach K; Poels J; Burgeon E; Vanden Broeck J; Janecka A
Life Sci; 2006 Aug; 79(11):1094-9. PubMed ID: 16624333
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
Fichna J; do-Rego JC; Chung NN; Lemieux C; Schiller PW; Poels J; Broeck JV; Costentin J; Janecka A
J Med Chem; 2007 Feb; 50(3):512-20. PubMed ID: 17266203
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of opioid receptor ligands by aequorin luminescence-based calcium assay.
Fichna J; Gach K; Piestrzeniewicz M; Burgeon E; Poels J; Broeck JV; Janecka A
J Pharmacol Exp Ther; 2006 Jun; 317(3):1150-4. PubMed ID: 16497786
[TBL] [Abstract][Full Text] [Related]
5. Identification of endomorphin-1 and endomorphin-2 binding sites in human mu-opioid receptor by antisense oligonucleotide strategy.
Fichna J; Gach K; Perlikowska R; Poels J; Vanden Broeck J; Szemraj J; Janecka A
Chem Biol Drug Des; 2008 Dec; 72(6):507-12. PubMed ID: 19090917
[TBL] [Abstract][Full Text] [Related]
6. Receptor reserve reflects differential intrinsic efficacy associated with opioid diastereomers.
Carliss RD; Keefer JF; Perschke S; Welch S; Rich TC; Weissman AD
Pharmacol Biochem Behav; 2009 May; 92(3):495-502. PubMed ID: 19463265
[TBL] [Abstract][Full Text] [Related]
7. [Binding characteristics of new synthesized opioid receptor ligands to cloned mu opioid receptors stably expressed in CHO cell].
Hu P; Ye CY; Qiu ZB; Yang HF; Zhang DC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):79-82. PubMed ID: 12905615
[TBL] [Abstract][Full Text] [Related]
8. Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure.
Fichna J; do-Rego JC; Janecki T; Staniszewska R; Poels J; Broeck JV; Costentin J; Schiller PW; Janecka A
Bioorg Med Chem Lett; 2008 Feb; 18(4):1350-3. PubMed ID: 18207400
[TBL] [Abstract][Full Text] [Related]
9. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
10. In vivo neurochemical evidence that delta1-, delta2- and mu2-opioid receptors, but not mu1-opioid receptors, inhibit acetylcholine efflux in the nucleus accumbens of freely moving rats.
Kiguchi Y; Aono Y; Watanabe Y; Yamamoto-Nemoto S; Shimizu K; Shimizu T; Kosuge Y; Waddington JL; Ishige K; Ito Y; Saigusa T
Eur J Pharmacol; 2016 Oct; 789():402-410. PubMed ID: 27445235
[TBL] [Abstract][Full Text] [Related]
11. mu-Opioid agonists inhibit the enhanced intracellular Ca(2+) responses in inflammatory activated astrocytes co-cultured with brain endothelial cells.
Hansson E; Westerlund A; Björklund U; Olsson T
Neuroscience; 2008 Sep; 155(4):1237-49. PubMed ID: 18692967
[TBL] [Abstract][Full Text] [Related]
12. Modulation of agmatine on calcium signal in morphine-dependent CHO cells by activation of IRAS, a candidate for imidazoline I1 receptor.
Wu N; Su RB; Liu Y; Lu XQ; Zheng JQ; Cong B; Li J
Eur J Pharmacol; 2006 Oct; 548(1-3):21-8. PubMed ID: 16962578
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibitory effects of mu-opioids on substance P- and capsaicin-induced nociceptive behavior in mice.
Watanabe H; Nakayama D; Yuhki M; Sawai T; Sakurada W; Katsuyama S; Hayashi T; Watanabe C; Mizoguchi H; Fujimura T; Sakurada T; Sakurada S
Peptides; 2006 Apr; 27(4):760-8. PubMed ID: 16226344
[TBL] [Abstract][Full Text] [Related]
14. Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat mu-opioid receptor in binding of mu-selective ligands.
Xu H; Lu YF; Partilla JS; Zheng QX; Wang JB; Brine GA; Carroll FI; Rice KC; Chen KX; Chi ZQ; Rothman RB
Synapse; 1999 Apr; 32(1):23-8. PubMed ID: 10188634
[TBL] [Abstract][Full Text] [Related]
15. Effect of agmatine on DAMGO-induced mu-opioid receptor down-regulation and internalization via activation of IRAS, a candidate for imidazoline I(1) receptor.
Gao Y; Li F; Wu N; Su RB; Liu Y; Lu XQ; Liu Y; Li J
Eur J Pharmacol; 2008 Dec; 599(1-3):18-23. PubMed ID: 18845140
[TBL] [Abstract][Full Text] [Related]
16. Transient overexpression of kappa and mu opioid receptors using recombinant adenovirus vectors.
Zhen Z; Bradel-Tretheway BG; Dewhurst S; Bidlack JM
J Neurosci Methods; 2004 Jul; 136(2):133-9. PubMed ID: 15183265
[TBL] [Abstract][Full Text] [Related]
17. Effects of various mu- and delta-opioid ligands on food intake in the meat-type chick.
Bungo T; Dodo K; Kawamura K; Izumi T; Ueda H
Physiol Behav; 2005 Aug; 85(5):519-23. PubMed ID: 16054662
[TBL] [Abstract][Full Text] [Related]
18. Activation of opioid mu-receptor by sinomenine in cell and mice.
Wang MH; Chang CK; Cheng JH; Wu HT; Li YX; Cheng JT
Neurosci Lett; 2008 Oct; 443(3):209-12. PubMed ID: 18692550
[TBL] [Abstract][Full Text] [Related]
19. Competitive displacement binding assay on rat brain sections and using a beta-imager: application to mu-opioid ligands.
Poisnel G; Quentin T; Barré L; Coquerel A; Debruyne D
J Neurosci Methods; 2006 Jun; 154(1-2):60-7. PubMed ID: 16423409
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
